Previous 10 | Next 10 |
metamorworks/iStock via Getty Images F-star Therapeutics (FSTX) has added ~14.3% in the pre-market after announcing a licensing agreement with AstraZeneca (AZN) for next-generation Stimulator of Interferon Genes ((STING)) inhibitor compounds. Per the terms, Anglo-Swedish d...
metamorworks/iStock via Getty Images F-star Therapeutics (FSTX) has added ~14.3% in the pre-market after announcing a licensing agreement with AstraZeneca (AZN) for next-generation Stimulator of Interferon Genes ((STING)) inhibitor compounds. Per the terms, Anglo-Swedish d...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immu...
Two new sample breakout stocks for Week 25 with better than 10% short-term upside potential. This past week, the peak gains were in SOL +9.3% and INBX +7.3% with the Market and S&P 500 Momentum Gauges® turning the most negative since February. 2021 MDA minimal returns are...
Photo by goir/iStock via Getty Images Biogen’s Aducanumab pricing could reignite debate on drug price: Citi With a $56K/ year price tag for its newly-approved Alzheimer's disease treatment Aduhelm (aducanumab), Biogen (BIIB) has already generated criticism from lawmakers. The comp...
F-star Therapeutics, Inc. (FSTX) Q1 2021 Earnings Conference Call May 17, 2021 9:00 AM ET Company Participants Lindsey Trickett - Vice President of Investor Relations Eliot Forster - President and Chief Executive Officer Darlene Deptula-Hicks - Chief Financial Officer Conference Call Particip...
The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: F-star Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
F-star Therapeutics (FSTX): Q1 GAAP EPS of -$1.08 beats by $0.08.Revenue of $2.92M (+114.7% Y/Y) beats by $1.72M.Press Release For further details see: F-star Therapeutics EPS beats by $0.08, beats on revenue
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cance...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today t...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can...